Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis (Q57305845)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author

Gabriela A. Berlakovich

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Farsad Eskandary

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Franz König

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Thomas Wekerle

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Christoph Schwarz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Sophie Mayerhoffer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Rudolf Steininger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Thomas Soliman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Bruno Watschinger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ferdinand Mühlbacher

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Georg A Böhmig

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

6 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

published in

Transplant International

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

820-827

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

Belatacept: from rational design to clinical application

1 March 2020

cites work

1 reference

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

Five-year safety and efficacy of belatacept in renal transplantation

21 January 2018

1 reference

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials.

21 January 2018

1 reference

Use of kidney function end points in kidney transplant trials: a systematic review.

21 January 2018

1 reference

Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand?

21 January 2018

1 reference

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study

21 January 2018

1 reference

Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation

21 January 2018

1 reference

MDRD equations for estimation of GFR in renal transplant recipients

21 January 2018

1 reference

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial

21 January 2018

1 reference

Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.

21 January 2018

1 reference

Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma

21 January 2018

1 reference

Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation

21 January 2018

1 reference

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

21 January 2018

1 reference

Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection

21 January 2018

1 reference

Summary of the US FDA approval of belatacept

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TRI.12544

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25703346%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference